Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy.
Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy; Gynecopathology and Breast Pathology Unit, Department of Woman's Health Science, Agostino Gemelli University Polyclinic, Rome, Italy.
Pathol Res Pract. 2022 Apr;232:153812. doi: 10.1016/j.prp.2022.153812. Epub 2022 Feb 22.
To assess the prognostic value of Bcl2 and Bcl6 in primary cutaneous diffuse large B-cell lymphoma (pcDLBCL), through a systematic review and meta-analysis.
Electronic databases were searched from their inception to April 2021 for studies reporting Bcl2 and Bcl6 expression and survival outcomes in pcDLBCL series. Kaplan-Meier and Cox regression survival analyses with hazard ratio calculation were performed for overall survival (OS), with a significant p-value< 0.05.
Eight studies with 148 patients were included. OS was significantly decreased in Bcl2-pos itive pcDLBCLs (5-year OS= 52.9 ± 5.2%) compared to Bcl2 negative pcDLBCLs (5-year OS= 86.6 ± 7.2%), with a HR of 4.615 (95% CI, 1.827-11.657; p = 0.001); no significant difference in OS was found between Bcl6-positive pcDLBCLs (5-year OS= 61.3 ± 6.5%) and Bcl6-negative pcDLBCLs (5-year OS= 56.8 ± 7.2%), with a HR of 0.789 (95% CI, 0.462-1.350; p = 0.388).
In pcDLBCL, Bcl2 expression is a strong unfavourable prognostic marker; Bcl6 does not seem to be associated with survival instead. Further studies are necessary in this field.
通过系统评价和荟萃分析，评估 Bcl2 和 Bcl6 在原发性皮肤弥漫性大 B 细胞淋巴瘤（pcDLBCL）中的预后价值。
从建库到 2021 年 4 月，电子数据库检索了报道 pcDLBCL 系列中 Bcl2 和 Bcl6 表达与生存结果的研究。进行 Kaplan-Meier 和 Cox 回归生存分析，计算风险比，以评估总生存期（OS），显著 p 值<0.05。
纳入 8 项研究共 148 例患者。Bcl2 阳性 pcDLBCL 的 OS 明显低于 Bcl2 阴性 pcDLBCL（5 年 OS=52.9±5.2%对 86.6±7.2%），风险比为 4.615（95%CI，1.827-11.657；p=0.001）；Bcl6 阳性 pcDLBCL 的 OS 与 Bcl6 阴性 pcDLBCL 之间无明显差异（5 年 OS=61.3±6.5%对 56.8±7.2%），风险比为 0.789（95%CI，0.462-1.350；p=0.388）。
在 pcDLBCL 中，Bcl2 表达是一个强烈的不良预后标志物；Bcl6 似乎与生存无关。该领域需要进一步研究。
